In contrast to the aforementioned system, in blood cancers, where increased mutational load is potentially advantageous for tumor progression [45], we observe that the inclusion of repeat-associated novel exons is suppressed potentially as a consequence of METTL3’s role as an oncogene and driver of AML [46]. The gene discussed is METTL3; the disease is hematopoietic and lymphoid system neoplasm.